[Pubmed] Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections: A prospective coho

[RSS-Bot]

Clin Immunol. 2023 Dec 22:109879. doi: 10.1016/j.clim.2023.109879. Online ahead of print.

ABSTRACT

The impact of Omicron infections on the clinical outcome and immune responses of myasthenia gravis (MG) remained largely unknown. From a prospective multicenter MG cohort (n = 189) with 197 myasthenic crisis (MC), we finally included 41 independent MG patients to classify into two groups: the Omicron Group (n = 13) and the Control Group (n = 28). In this matched cohort study, all-cause mortality was 7.69% (1/13) in Omicron Group and 14.29% (4/28) in Control Group. A higher proportion of elevated serum IL-6 was identified in the Omicron Group (88.89% vs 52.38%, P = 0.049). In addition, the proportions of CD3+CD8+T in lymphocytes and Tregs in CD3+CD4+ T cells were significantly elevated in the Omicron Group (both P = 0.0101). After treatment, the Omicron Group exhibited a marked improvement in MG-ADL score (P = 0.026) and MG-QoL-15 (P = 0.0357). MCs with Omicron infections were associated with elevated serum IL-6 and CD3+CD8+T response. These patients tended to present a better therapeutic response after fast-acting therapies and anti-IL-6 treatment.

PMID:38142901 | DOI:10.1016/j.clim.2023.109879


Source: https://pubmed.ncbi.nlm.nih.gov/3814290 ... 4&v=2.18.0